Table 1.
Summary of demographic and clinical characteristics of 48 adult patients with ALL who developed peripheral neuropathy after combination chemotherapy that included vncristine (cases) and 48 adult patients matched for race, sex and time on protocol treatment who did not develop grade 2-4 neuropathy (controls).
| Demographic and clinical characteristics | Cases (48) | Controls (48) | P value | |
|---|---|---|---|---|
| Age (Years) Median | 36.5 (17.2-71.2) | 34.5 (18.2-76.1) | 0.4479 | |
| Sex | Female | 22 (45.8%) | 22 (45.8%) | 1.000 |
| Male | 26 (54.2%) | 26 (54.2%) | ||
| Ethnicity | Hispanic | 3 (6.3%) | 4 (8.3%) | 0.4553 |
| Non-Hispanic | 38 (79.2%) | 41 (85.4%) | ||
| Unknown | 7 (14.6%) | 3 (6.3%) | ||
| Race | Hispanic American | 1(2.1%) | 2 (4.2%) | 1.000 |
| Indian subcontinent | 1(2.1%) | 0 (0.0%) | ||
| Unknown | 1(2.1%) | 1 (2.1%) | ||
| White | 45 (93.8%) | 45 (93.8%) | ||
| BSA (m2) Median (range) | 2.0 (1.5- 2.5) | 1.89 (1.5- 2.4) | 0.0648 | |
| Alliance ALL Protocol | 10102 | 25 (52.1%) | 25 (52.1%) | 1.000 |
| 10403 | 9 (18.8%) | 9 (18.8%) | ||
| 19802 | 14 (29.2%) | 14 (29.2%) | ||
| Highest Neuropathy Grade | 0 | 0 | 11 | |
| 1 | 0 | 37 | ||
| 2 | 29 | 0 | ||
| 3 | 17 | 0 | ||
| 4 | 2 | 0 | ||
| Vincristine Cumulative Dose (mg/m2)* Median (range) | 5.7 (1.3- 30.4) | 10.4 (2.1- 46.8) | 0.0008 | |
*
There was no difference in the cumulative dosage of vincristine in cases and controls, when assessed at the time when neuropathy was documented in the cases.